Next Quarterly Earnings
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Ascendis Pharma ADR, headquartered in Denmark, is a leading biopharmaceutical company specializing in developing innovative therapies using its proprietary TransCon technology platform. The company focuses on optimizing known active ingredients to address the needs of patients with rare diseases.
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Ascendis Pharma ADR is scheduled to report its next quarterly earnings on 11/11/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Ascendis Pharma ADR last reported quarterly earnings on 8/13/2026 (Q2 2026). Earnings per share (EPS) came in at 3.22 USD.
Across its last 3 earnings reports, Ascendis Pharma ADR stock moved by ±3.2% on average the following day. The largest reaction was +4.3% on 05/07/2026; 1 of 3 reactions were positive.
Ascendis Pharma ADR has beaten analyst EPS estimates in 2 of its last 3 evaluated quarters (beat rate: 66.7%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 3 report dates (close to close).
Basis: 3 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.